Simbie AI vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 41)
Simbie AI logo

Simbie AI

EmergingHealthcare

General

SF EHR-integrated AI voice agent for independent medical practices handling scheduling and insurance verification; YC W25 $500K at 83x revenue growth reducing staff-to-physician ratios by one-third.

AI VisibilityBeta
Overall Score
C41
Category Rank
#351 of 596
AI Consensus
74%
Trend
down
Per Platform
ChatGPT
46
Perplexity
36
Gemini
44

About

Simbie AI is a San Francisco-based healthcare technology company developing EHR-integrated AI voice agents that serve as 24/7 multilingual administrative staff for independent medical practices — handling scheduling, insurance verification, prescription refill requests, patient communications, and clinical administrative tasks that currently require front-desk staff handling hundreds of calls daily. Founded by Dr. Natalia Khosla and Rachel O'Driscoll and backed by Y Combinator (W25) with $500,000 raised, Simbie achieved 83x revenue growth since its January 2025 launch with zero churn, reducing staff-to-physician ratios by one-third and recovering 10-20% of revenue previously lost to missed calls.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

41
Overall Score
93
#351
Category Rank
#1
74
AI Consensus
80
down
Trend
stable
46
ChatGPT
94
36
Perplexity
89
44
Gemini
94
44
Claude
92
38
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.